CompletedPhase 3

Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer

United States116 participantsStarted 2006-10

Plain-language summary

RATIONALE: Topical sunscreen may be effective in preventing skin rash caused by treatment with drugs such as erlotinib or cetuximab. It is not yet known whether topical sunscreen is more effective than a placebo in preventing skin rash in patients receiving drugs such as erlotinib or cetuximab for cancer. PURPOSE: This randomized phase III trial is studying topical sunscreen to see how well it works compared with a placebo in preventing skin rash in patients receiving drugs such as erlotinib or cetuximab for cancer.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Diagnosis of cancer * Receiving ≥ 1 of the following epidermal growth factor receptor (EGFR) inhibitor treatments: * Gefitinib * Cetuximab * Erlotinib * Panitumumab * ICR-62 * Matuzumab * CI-1033 * EGFR treatment must have begun within the past 3 days * No rash (of any etiology) at study entry PATIENT CHARACTERISTICS: * Able to apply sunscreen on face, trunk, and extremities * Able to complete questionnaire(s) * No history of allergic reactions or severe intolerance to sunscreen or its derivatives * No history of skin problems likely to reoccur during treatment * Must avoid heavy sun exposure, especially during the hours of noon to 4 pm daily PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No concurrent tanning bed usage * No other concurrent topical sunscreens

What they're measuring

Incidence and severity of rash development by Skindex questionnaire

Timeframe: Up to 8 weeks

Trial details

NCT IDNCT00362986

SponsorAlliance for Clinical Trials in Oncology

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2007-07